## Quantification of the $\alpha_v\beta_6$ Integrin by PET/CT Imaging in the Lungs of Patients After SARS-CoV2 Infection and Comparison to Fibrotic Lungs

**TO THE EDITOR:** We were interested to read the recent article by Foster et al. (*1*) describing early experience of $\alpha_v\beta_6$ PET/CT imaging of the lungs after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

We would like to point out that the suggestion that the $\alpha_v\beta_6$ uptake in lung regions affected by SARS-CoV-2 is 3 times that which we reported previously for fibrotic lung (*2*) may be misleading. Foster et al. report an $SUV_{max}$ of approximately 3.0 in SARS-CoV-2 and compare this with our reported value of 1.03 in subjects with idiopathic pulmonary fibrosis. However, our value is the $SUV_{mean}$ averaged over the whole lung volume, which will be systematically lower than $SUV_{max}$. Although we did not perform an equivalent analysis, and the color scale in our example images (Lukey et al. (*2*), Fig. 1) was chosen to enable comparison with the healthy participants rather than visualization of the maximal value, we can confirm qualitatively that localized SUVs of 3.0 or more were observed widely in the fibrotic lung regions in our study.

Clearly, more data and appropriate analyses (*3*) would be needed to make a valid quantitative comparison, particularly given the potential influence of tissue fraction (*4*) and the known (micro)-vascular component of the SARS-CoV-2 disease mechanism (*5*), which might influence the blood signal.

We look forward to seeing more results from this important work in due course.

### DISCLOSURE

Pauline T. Lukey was previously an employee of GlaxoSmithKline and is currently a shareholder. She now works or has worked as an independent consultant to GlaxoSmithKline R&D, the Francis Crick Institute, Galecto, Mereo BioPharma, BerGenBio, Revolo, DJS Antibodies. Frederick J. Wilson is an employee and shareholder of GSK. No other potential conflict of interest relevant to this article was reported.

### REFERENCES

1. Foster CC, Davis RA, Hausner SH, Sutcliffe JL. αvβ6-targeted molecular PET/CT imaging of the lungs after SARS-CoV-2 infection. *J Nucl Med.* 2020;61:1717–1719.
2. Lukey PT, Coello C, Gunn R, et al. Clinical quantification of the integrin αvβ6 by [$^{18}$F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL study). *Eur J Nucl Med Mol Imaging.* 2020;47:967–979.
3. Chen DL, Cheriyan J, Chilvers ER, et al. Quantification of lung PET images: challenges and opportunities. *J Nucl Med.* 2017;58:201–207.
4. Lambrou T, Groves AM, Erlandsson K, et al. The importance of correction for tissue fraction effects in lung PET: preliminary findings. *Eur J Nucl Med Mol Imaging.* 2011; 38:2238–2246.
5. Lins M, Vandevenne J, Thillai M, et al. Assessment of small pulmonary blood vessels in COVID-19 patients using HRCT. *Acad Radiol.* 2020;27:1449–1455.

**Pauline T. Lukey***
**Frederick J. Wilson**
*Target to Treatment Consulting Ltd.,
Stevenage, United Kingdom
E-mail: paulinelukey@target2treatment.com

## Potential Theranostic Role of Bone Marrow Glucose Metabolism on Baseline $^{18}$F-FDG PET/CT in Metastatic Melanoma

**TO THE EDITOR:** We have read with great interest the article "Prognostic Value of Bone Marrow Metabolism on Pretreatment $^{18}$F-FDG PET/CT in Patients with Metastatic Melanoma Treated with anti-PD-1 Therapy" from Nakamoto et al. (*1*). Although *The Journal of Nuclear Medicine* has published several papers highlighting the clinical value of sequential $^{18}$F-FDG PET/CT for response assessment (*2,3*), this new article showed that baseline $^{18}$F-FDG PET/CT could also be used to guide treatment decisions.

To this end, the authors studied a population of 92 patients with a diagnosis of metastatic melanoma treated with immune checkpoint inhibitors (ICIs) (*1*). ICIs included anti-PD1 as single-agent (88%) or in combination (12%) with anticytotoxic T-lymphocyte antigen-4 or antilymphocyte activation gene-3. The authors have evaluated whether patients' overall survival (OS) could be predicted by biomarkers such as demographic or clinical ($n = 4$), biologic ($n = 1$), pathologic ($n = 1$), and imaging variables extracted from baseline and on treatment $^{18}$F-FDG PET/CT ($n = 6$).

### Confirming Prognostic Significance of BM Metabolism

In this population, the authors confirmed that noninvasive measurement of glucose metabolism on nontumoral bone marrow can be used to predict OS in patients with a diagnosis of advanced melanoma treated with ICIs (*4*). They demonstrated that mean bone marrow–to–liver uptake ratio ($BLR_{mean}$ = bone marrow $SUV_{mean}$/liver $SUV_{mean}$) was the most valuable prognostic imaging biomarker. High baseline $BLR_{mean}$ predicted a significantly poor progression-free survival and OS. The finding that bone marrow glucose metabolism is an imaging biomarker correlated with survival is of interest and aligns with findings in existing literature (*4,5*). Hence, this letter aims to share with the readership of *The Journal of Nuclear Medicine* (*JNM*) recent publications in the field to provide a deeper understanding on the relationship between bone marrow and clinical outcomes.

### Association Between Bone Marrow (BM) Metabolism and Systemic Inflammation

In a recent review published in *JNM*, tumor and bone marrow glucose metabolism were analyzed in 12 studies including 2,588 cancer patients who underwent both $^{18}$F-FDG PET/CT scans and biochemical assessments with blood samples (*6*). Most studies showed that

these imaging biomarkers were associated with clinical outcomes as well as systemic inflammatory responses (high C-reactive protein, low albumin, high neutrophils or leukocytes or platelets).

## Association Between Bone Marrow (BM) Metabolism and Tumor Immune Environment

Because there is a cross talk between the tumor immune environment and BM, our team evaluated the association between bone marrow glucose metabolism and transcriptomics in patients with a diagnosis of metastatic cutaneous melanoma treated with ICIs (4). To this end, we assessed the tumor immune microenvironment using transcriptomics analysis on tumor tissues. Strikingly, high bone marrow metabolism was associated with an upregulation of genes related to dendritic cells, regulatory T cell activity, and memory T cells phenotypes (4).

Of note, this was a pilot study and the major molecular pathways determining the cross talk between the BM and tumor immune environment remain to be elucidated. For now, preclinical studies showed that tumor growth in melanoma seems to play a critical role in reprogramming the host immune system by regulating hematopoiesis, which might be associated with the expansion of immunosuppressive cells such as tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells (MDSCs) (7).

In patients with gynecologic cancer, high BM glucose metabolism was mainly due to the production of granulocyte colony-stimulating factor (G-CSF) by tumor cells (8). Patients with high BM glucose metabolism displayed an im-munosuppressive phenotype with increased MDSCs and decreased CD8+ T cells (8).

Prospective studies and translational studies correlating BM glucose metabolism with antitumor immunity are warranted. Continued efforts need to be made and should focus on improving our understanding of physiopathologic concepts. We have to clarify the association between baseline bone marrow glucose metabolism and the presence of an immunosuppressive environment. This is necessary to unravel further cancer-related inflammation and immunosuppressive phenotypes associated with immunotherapy resistance through the use of quantitative transcriptome analyses of tumor, lymphoid tissue biopsies, and immuno-PET imaging.

## Potential Theranostic Approaches

The demonstration of the prognostic value of BM glucose metabolism and of its association with tumor immune environment offers a springboard to exciting, new theranostic research. Novel therapies blocking immunosuppressive agents, such as MDSCs, are indeed under investigation (9) to potentiate ICIs. The underlying assumption is that glucose metabolism on tissues with medullary and extramedullary hematopoiesis could be associated with tumor-induced immune suppression. For instance, preimmunotherapy ^{18}F-FDG PET/CT that explores bone marrow might be a relevant assay to predict response to MDSCs-blockade therapies, in combination with ICI (10).

In conclusion, the scientific community has demonstrated that BM glucose metabolism measured on ^{18}F-FDG PET is associated with immunotherapy outcomes in patients with metastatic melanoma. The next step is to pursue efforts with prospective and large multicenter studies that would ensure a deeper understanding on how this specific biomarker could be used as a clinical decision support tool in patients with metastatic melanoma treated with ICIs.

## DISCLOSURE

No potential conflict of interest relevant to this article was reported.

## REFERENCES

1. Nakamoto R, Zaba LC, Liang T, et al. Prognostic value of bone marrow metabolism on pretreatment 18 F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy. *J Nucl Med.* February 5, 2021 [Epub ahead of print].
2. Seban R-D, Schwartz LH, Bonardel G, Dercle L. Diagnosis of hyperprogressive disease in patients treated with checkpoint inhibitors using ^{18}F-FDG PET/CT. *J Nucl Med.* 2020;61:1404–1405.
3. Dercle L, Seban R-D, Lazarovici J, et al. ^{18}F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor. *J Nucl Med.* 2018;59:15–24.
4. Seban R-D, Nemer JS, Marabelle A, et al. Prognostic and theranostic ^{18}F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. *Eur J Nucl Med Mol Imaging.* 2019;46:2298–2310.
5. Prévost S, Boucher L, Larivée P, Boileau R, Bénard F. Bone marrow hypermetabolism on ^{18}F-FDG PET as a survival prognostic factor in non-small cell lung cancer. *J Nucl Med.* 2006;47:559–565.
6. Dolan RD, McLees NG, Irfan A, et al. The relationship between tumor glucose metabolism and host systemic inflammatory responses in patients with cancer: a systematic review. *J Nucl Med.* 2019;60:467–471.
7. Kamran N, Li Y, Sierra M, et al. Melanoma induced immunosuppression is mediated by hematopoietic dysregulation. *OncoImmunology.* 2017;7:e1408750.
8. Shimura K, Mabuchi S, Komura N, et al. Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer. *Sci Rep.* 2021;11:2257.
9. Holtzhausen A, Harris W, Ubil E, et al. TAM family receptor kinase inhibition reverses MDSC-mediated suppression and augments anti-PD-1 therapy in melanoma. *Cancer Immunol Res.* 2019;7:1672–1686.
10. Liu Y, Wei G, Cheng WA, et al. Targeting myeloid-derived suppressor cells for cancer immunotherapy. *Cancer Immunol Immunother.* 2018;67:1181–1195.

**Romain-David Seban**
**Laurence Champion**
**Izza Muneer**
**Shwe Synn**
**Lawrence H. Schwartz**
**Laurent Dercle***
**Columbia University Medical Center*
*New York, New York*

# Is ^{18}F-FDG PET/CT Effective in Identifying True Residual Disease After Treatment of Pediatric PTLD?

**TO THE EDITOR:** Limited data are available describing the role of ^{18}F-FDG PET/CT in assessing treatment response in pediatric posttransplant lymphoproliferative disease (PTLD). In this journal, Montes de Jesus reported 8 patients who underwent end-of-treatment ^{18}F-FDG PET/CT. Of 4 positive scans, 1 was true-positive and the remaining 3 were false-positive. There were 4 true-negative and 1 false-negative results. In 2 of the false-positive cases, a 2-y follow-up did not reveal PTLD, and in 1 case a biopsy revealed no evidence of PTLD. For the false-negative end-of-treatment ^{18}F-FDG PET/CT, a biopsy 2 mo later revealed residual monomorphic PTLD (1). Similar data were reported in adult PTLD. Van Keerberghen reported positive predictive values (PPVs) and negative predictive values (NPVs) for disease recurrence of 13% and 85% for interim and 33% and 87% for end-of-treatment ^{18}F-FDG PET/CT, respectively. Negative interim or negative end-of-treatment ^{18}F-FDG PET/CT correlated with durable remissions (2). A lower false-positive rate was